Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ENCEFALO: Sequential Targeted and Immunotherapy in BRAF+ Melanoma Brain Mets
NCT06887088Phase 2Recruiting
- Start
- May 2025
- Primary completion
- Jan 2028
- Modality
- Immune Checkpoint Inhibitors, Antibody Conjugates, Engineered Antibody Formats
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of fianlimab and cemiplimab in melanoma. Primary endpoint: Intracranial Progression-Free Survival at 6 months. Started May 2025; status: recruiting.
02
Drugs
fianlimabcemiplimab
03
Conditions
melanoma
Beyond the preview
Go deeper on NCT06887088.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06887088.